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Cryptococcus neoformans and C. gattii are fungal pathogens that cause life-threatening
disease. These fungi commonly enter their host via inhalation into the lungs where
they encounter resident phagocytes, including macrophages and dendritic cells, whose
response has a pronounced impact on the outcome of disease. Cryptococcus has
complex interactions with the resident and infiltrating innate immune cells that, ideally,
result in destruction of the yeast. These phagocytic cells have pattern recognition
receptors that allow recognition of specific cryptococcal cell wall and capsule
components. However, Cryptococcus possesses several virulence factors including a
polysaccharide capsule, melanin production and secretion of various enzymes that aid
in evasion of the immune system or enhance its ability to thrive within the phagocyte.
This review focuses on the intricate interactions between the cryptococci and innate
phagocytic cells including discussion of manipulation and evasion strategies used by
Cryptococcus, anti-cryptococcal responses by the phagocytes and approaches for
targeting phagocytes for the development of novel immunotherapeutics.
Keywords: cryptococcosis, Cryptococcus neoformans, Cryptococcus gattii, Cryptococcus, fungal immunity,
innate immune response, medical mycology
Cryptococcus neoformans AND C. gattii
Cryptococcosis is a disease predominantly caused by the species Cryptococcus neoformans and
C. gattii in humans and other mammals (Kwon-Chung et al., 2014). Cryptococcus sp. are generally
encountered in the environment. C. gattii is commonly found in tropical and subtropical regions,
however, the species is expanding its reach as evidenced by the recent outbreak inVancouver Island,
British Columbia, Canada and the Paciﬁc Northwest of the United States (reviewed in Hole and
Wormley, 2012; Kwon-Chung et al., 2014). Until recently, Cryptococcus sp. have been categorized
into only these two species and subcategorized by serotype (A–D) and molecular type (VNI-VNIV,
and VGI-VGIV; reviewed in Kwon-Chung et al., 2014). Currently, seven species of C. gattii/C.
neoformans have been identiﬁed based on genotyping studies that have revealed signiﬁcant genetic
diversity within the species complex (Hagen et al., 2015). For the purposes of this review to ensure
accurate reference to strains used in the discussed studies, we will refer to the organisms based on
their previous C. neoformans (serotype A and D) and C. gattii (serotype B and C) nomenclature
unless otherwise speciﬁed.
Interestingly, despite sharing 80–90% genomic identity (Kavanaugh et al., 2006), C. neoformans
and C. gattii aﬀect diﬀerent patient populations and with diﬀerent disease manifestations. The
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infectious propagule of both species is inhaled into the
lungs and the infection is often controlled by the host’s
immune system (Park and Mehrad, 2009). C. neoformans,
however, predominantly causes disease in immunocompromised
individuals, including AIDS patients and those undergoing
immunosuppressive therapies, resulting in pneumonia and has a
predilection to disseminate to the central nervous system (CNS)
leading to life threatening meningoencephalitis (Powderly, 1993;
van der Horst et al., 1997; Saag et al., 2000; Husain et al.,
2001; Liu et al., 2012; Kwon-Chung et al., 2014; Sorrell et al.,
2015). C. gattii principally causes disease in healthy individuals
with no discernable underlying condition (Marr et al., 2012;
Lizarazo et al., 2014). However, the idea that C. gattii is a primary
pathogen is being questioned as anti-granulocyte-macrophage
colony-stimulating factor (GM-CSF) autoantibodies have been
detected in C. gattii infected patients but not in samples from
healthy donors (Saijo et al., 2014; Kwon-Chung and Saijo, 2015).
Thus, anti-GM-CSF autoantibodies could indicate an underlying
immunodeﬁciency that predisposes patients to C. gattii infection.
This demonstrates a need for more comprehensive screening
before classifying a patient as “immunocompetent” and further
examination of the C. gattii patient population. Another striking
diﬀerence between these two species is that C. gattii shows
little penchant for dissemination to the CNS compared to
C. neoformans (Ngamskulrungroj et al., 2012). Comparison of
two virulent strains of C. neoformans (strain H99) and C. gattii
(strain R265) revealed that even though C. gattii can cross
the blood-brain barrier (BBB), C. neoformans grew 10–100
times faster in naïve mouse blood and serum (Ngamskulrungroj
et al., 2012). This suggests that these two species have a
diﬀerent speciﬁcity for their target organ that is not yet fully
elucidated.
IMMUNE RESPONSE
The host has eﬃcient mechanisms for combating these
debilitating fungi. Initiation of a pro-inﬂammatory Th1-type
immune response, characterized by interleukin-2 (IL-2), IL-
12, IL-18, interferon-γ (IFN-γ) and tumor necrosis factor-α
(TNF-α), is protective against Cryptococcus (Huﬀnagle et al.,
1991; Aguirre et al., 1995; Huﬀnagle, 1996; Kawakami et al.,
1996, 1997a; Zhang et al., 1997, 2009; Huﬀnagle and Lipscomb,
1998; Olszewski et al., 2010). Additionally, generation of an
anti-inﬂammatory Th2-type immune response, characterized
by IL-4, IL-5, IL-13, and the immunoregulatory cytokine
IL-10, is associated with exacerbation of disease (Huﬀnagle
et al., 1998; Arora et al., 2005, 2011; Milam et al., 2007;
Muller et al., 2007; Chen et al., 2008; Jain et al., 2009;
Osterholzer et al., 2009b). In addition, a Th17-type response
characterized by IL-17A, IL-21, IL-22, IL-6, and TGF-β (Korn
et al., 2007, 2009; Onishi and Gaﬀen, 2010) has been shown
to contribute to anti-cryptococcal immune responses (Zhang
et al., 2009; Murdock et al., 2014). However, IL-17A and
signaling through the IL-17A receptor is not required for
clearance in a protective model of cryptococcosis (Wozniak et al.,
2011a).
Experimental studies in mice with certain C. neoformans
strains, including the highly virulent strain H99, results in a
Th2-type polarized response which is not protective (Huﬀnagle
et al., 1998; Milam et al., 2007; Muller et al., 2007; Chen
et al., 2008; Xiao et al., 2008; Osterholzer et al., 2009b).
However, studies using a C. neoformans strain H99 that was
genetically engineered to express and secrete murine IFN-γ
(H99γ; Wormley et al., 2007) showed that inoculation of mice
with strain H99γ results in protective Th1-type responses and IL-
17 production, increased leukocyte inﬁltration and production of
pro-inﬂammatory cytokines/chemokines (Wormley et al., 2007;
Wozniak et al., 2009, 2011a). In addition, immunization of mice
with H99γ yields 100% protection against subsequent challenge
withWTC. neoformansH99, providing evidence that vaccination
against C. neoformans is possible (Wormley et al., 2007; Wozniak
et al., 2009; Hardison et al., 2010, 2012). Furthermore, studies
examining T cell depleted mice showed that mice immunized
with H99γ and challenged with WT C. neoformans during T
cell depletion were also protected against challenge, showing that
immune-compromised hosts could be protected (Wozniak et al.,
2011b). The majority of studies utilize C. neoformans as a model
organism to assess protection via Th1 and Th17-type responses,
however, several studies have suggested that protection against
C. gattii employs a diﬀerent mechanism. It has been shown that
infection with C. gattii leads to suppression of host’s immune
responses, including decreased leukocyte recruitment and pro-
inﬂammatory cytokine production (Dong and Murphy, 1995;
Wright et al., 2002; Cheng et al., 2009). This could provide an
indication as to how C. gattii is able to aﬀect immunocompetent
individuals, while C. neoformans predominantly causes disease in
the immunocompromised populations.
It is crucial that the host immune responses will eradicate or
limit the spread of fungal pathogens from the lung before they
are able to disseminate. The host relies on pulmonary innate
immune cells as its ﬁrst line of defense against Cryptococcus
sp. These include the phagocytic macrophages, dendritic cells
(DCs) and neutrophils. When the yeast-like cell or basidiospore
is encountered by the phagocyte, the phagocytic cell will engulf
the invading organism forming a phagosome. Ideally, the
phagosome will mature, acidify following fusion with a lysosome
(forming the phagolysosome), and lead to the destruction of
the fungus. Cryptococcus sp. have evolved a number of defense
mechanisms and virulence factors that allow it to either survive
in the phagosome or avoid phagocytosis altogether (reviewed in
Kronstad et al., 2011; Kwon-Chung et al., 2014; Alspaugh, 2015).
The capsule of Cryptococcus is a complex and elaborate structure
composed of glucuronoxylomannan (GXM), galactoxylomannan
(GalXM) and, to a lesser degree, mannoproteins and is anchored
to the cell wall, which is composed of chitin, chitosan (acetylated
chitin), glucans and glycoprotein (Doering, 2009; O’Meara and
Alspaugh, 2012). The capsule is dynamic and dramatically
increases in thickness during infection or when cultured in host
inducing conditions (RPMI, 37◦C). Additionally, the capsule
functions to mask cryptococcal pathogen associated molecular
patterns (PAMPs) that can be recognized by pattern recognition
receptors (PRRs) on host cells, allowing Cryptococcus to evade
the immune system by preventing phagocytosis and can aid
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in providing protection against reactive oxygen species and
antimicrobial peptides (Zaragoza et al., 2008). Opsonization
of Cryptococcus with anti-capsular antibodies is required for
phagocytosis by immune cells due to the anti-phagocytic
properties of the capsule (reviewed in Kozel, 1993). The ability to
form “titan cells” is another anti-phagocytic mechanism utilized
by Cryptococcus. In the pulmonary environment, C. neoformans
cells can attain a large cell size varying from 50 to 100 μm
in diameter with varying degrees of capsule thickness making
them resistant to phagocytosis (Okagaki et al., 2010; Zaragoza
et al., 2010; Okagaki and Nielsen, 2012). Melanin production
by laccase is another virulence factor of C. neoformans and
C. gattii which serves to protect the organism from oxidative
stresses within the phagolysosome by breaking down host
substrates into reactive intermediates that can harm the host
(Zhu and Williamson, 2004; Panepinto and Williamson, 2006).
One example of this is the iron oxidase activity of laccase in the
phagolysosome that reduces potentially toxic Fenton reactants,
thus protecting Cryptococcus from the antifungal activity of
alveolar macrophages (Liu et al., 1999). Other virulence factors
include the ability to grow and proliferate at mammalian body
temperature (37◦C) and extracellular enzymes including laccases,
urease, and phospholipases (reviewed in Kronstad et al., 2011;
Almeida et al., 2015). In this review, we discuss interactions
between Cryptococcus sp. and innate phagocytic cells and how
these interactions determine the outcome of disease.
MACROPHAGES
Macrophage Activation
Resident alveolar macrophages which live within the lung
alveolar airspaces are critical to host defense as the ﬁrst line of
defense against pulmonary pathogens (Fels and Cohn, 1986).
Alveolar and inﬁltrating macrophages phagocytose and kill
invading pathogens and are capable of presenting antigen to
activated T cells to stimulate an adaptive immune response
in immunocompetent individuals. Interestingly, macrophages
have a dynamic plasticity which allows them to respond to
changes in their cytokine microenvironment and alter their
activation phenotype (Porcheray et al., 2005; Stout et al.,
2005; Gratchev et al., 2006; Sica and Mantovani, 2012; Davis
et al., 2013; Mantovani et al., 2013; Leopold Wager and
Wormley, 2014). Macrophage activation phenotype is broadly
classiﬁed as classical (M1) or alternative (M2) based on cytokine
production, extracellular receptor expression and secreted by-
products (Stout and Suttles, 2004; Mosser and Edwards, 2008;
Sica and Mantovani, 2012). Immune cells, including natural
killer (NK) cells, CD8+ T cells, and CD4+ T-helper 1 (Th1)-
type cells (Mosser and Edwards, 2008) respond to the pathogen
by secreting inﬂammatory cytokines, including IFN-γ which
signals macrophages to polarize toward an M1 phenotype
(Mantovani et al., 2004; Mosser and Edwards, 2008; Martinez
et al., 2009; Hussell and Bell, 2014). The markers commonly
used for identiﬁcation of M1 macrophages include inducible
nitric oxide synthase (iNOS), chemokine (C-X-C motif) ligand 9
(CXCL9), CXCL10, CXCL11, IL-12, and suppressor of cytokine
signaling 3 (SOCS3; reviewed in Mosser and Edwards, 2008;
Murray and Wynn, 2011; Leopold Wager and Wormley,
2014). M1 macrophages mediate host defense against microbial
pathogens via the generation of reactive oxygen and nitrogen
species (ROS and RNS, respectively; Ding et al., 1988). The
enzyme iNOS acts on the substrate L-arginine to produce nitric
oxide (NO), which has anti-cryptococcal properties (Figure 1;
Alspaugh and Granger, 1991; Arora et al., 2011; Hardison et al.,
2012; Davis et al., 2013; Leopold Wager et al., 2014, 2015).
Conversely, the enzyme arginase-1 (Arg-1) is a hallmark marker
of M2 macrophage activation and competes with iNOS for
this substrate producing L-ornithine and urea (Bogdan et al.,
2000). The Arg1 to iNOS ratio is often considered an indicator
of macrophage polarization phenotype as conditions leading
to the induction of M2 macrophages inhibit M1 macrophage
activation (Takeda et al., 1996; Van Dyken and Locksley,
2013).
The induction of M2 macrophage activation is mediated by
cytokines including IL-4 and IL-13 (Mosser and Edwards, 2008;
Mantovani et al., 2013; Van Dyken and Locksley, 2013). It was
recently shown that cryptococcal Ssa1, a heat shock protein 70
homolog, is secreted by C. neoformans and promotes early fungal
growth and a shift to M2 macrophage activation by stimulating
early production of IL-4 and IL-13 (Eastman et al., 2015). M2
macrophages contribute to the suppression and regulation of
inﬂammatory responses and play a pivotal role in wound-healing,
but are not antimicrobial against C. neoformans (Arora et al.,
2005, 2011; Mosser and Edwards, 2008; Martinez et al., 2009;
Hardison et al., 2010, 2012; Murray and Wynn, 2011; Davis
et al., 2013; Van Dyken and Locksley, 2013; Leopold Wager and
Wormley, 2014; LeopoldWager et al., 2014, 2015). C. neoformans
cells can survive inM2macrophages by using them as a protective
niche to evade recognition and killing by the host (reviewed
in Johnston and May, 2013). Immune cells including Th2-type
CD4+ T cells, basophils, eosinophils, mast cells and group 2
innate lymphoid cells (ILC2s) are sources of IL-4 and/or IL-
13 (Martinez et al., 2009; Murray and Wynn, 2011; Walker
and McKenzie, 2013; Walker et al., 2013). Recently, it was
shown that chitin, an integral part of the cryptococcal cell wall,
indirectly stimulates the production of IL-5 and IL-13 and can
trigger IL-4 production, resulting in M2 macrophage activation
(Reese et al., 2007; Van Dyken et al., 2014). IL-4 can stimulate
increased expression of mannose receptor (MR or CD206), the
ﬁrst described M2 macrophage activation-associated marker
(Stein et al., 1992). The commonly associated markers of M2
macrophage activation also include arginase1 (Arg1), found in
inﬂammatory zone 1 (FIZZ1, also known as resistin-like α or
Relm-α), and chitinase and chitinase-like molecules such as YM1
(Chi3l3) and YM2 (Mosser and Edwards, 2008; Murray and
Wynn, 2011).
Interestingly, macrophages, which are polarized toward an
M1 phenotype in the presence of IFN-γ, can re-polarize to anM2
phenotype when stimulated with IL-4. Similarly, M2 polarized
macrophages can re-polarize toward a functional M1 phenotype
in the presence of IFN-γ and are able to maintain functional
anti-cryptococcal activity (Stout et al., 2005; Gratchev et al.,
2006; Davis et al., 2013), signifying the critical importance of
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FIGURE 1 | Macrophage activation: protection against Cryptococcus is associated with M1 or classically activated macrophages. M1 macrophages
are induced by exposure to the Th1 cytokine IFN-γ. M1 macrophages are efficient killers as they have increased nitric oxide (NO) and ROS production. M2 or
alternatively activated macrophages are associated non-protective immune responses to Cryptococcus. M2 macrophages are not efficient killers and allow
Cryptococcus to grow and proliferate within the macrophage and may lead to dissemination. In addition, macrophage phenotype is plastic, allowing for
macrophages to switch between M1 and M2 phenotypes based on cytokines present in their environment.
the local cytokine milieu in driving macrophage polarization.
IFN-γ production by Th1-type T cells and NK cells can stimulate
M1 macrophage activation in a signal transducer and activator
of transcription (STAT) 1-dependent manner (Hu et al., 2002).
Studies utilizing the IFN-γ producing C. neoformans strain have
illustrated that STAT1 signaling in macrophages is required for
M1 macrophage activation and protection (Leopold Wager et al.,
2014; Leopold Wager et al., 2015). More in-depth discussion
of the macrophage polarization and C. neoformans infections
has been recently published elsewhere (Leopold Wager and
Wormley, 2014). Conversely, a clinical study recently showed
that despite elevated IFN-γ levels and pro-inﬂammatory factors
in the brains of two non-HIV cryptococcal meningitis patients,
poor phagocytosis and macrophages polarized to the non-
protective M2 phenotype was observed (Panackal et al., 2015).
This establishes that macrophage polarization in response to
C. neoformans in humans is quite complex and requires further
study.
Cryptococcus neoformans is sensitive to the NO produced by
M1 macrophages (Alspaugh and Granger, 1991; Aguirre and
Gibson, 2000; Rivera et al., 2002; Muller et al., 2007; Osterholzer
et al., 2009b; Stenzel et al., 2009; Zhang et al., 2009; Hardison et al.,
2010). C. neoformans is thought to down-regulate macrophage
iNOS RNA, thus mediating NO suppression (Kawakami et al.,
1997b; Chinen et al., 1999). Inhibition of iNOS results in M2
macrophage activation, loss of anti-cryptococcal activity and
progression of disease (Naslund et al., 1995; Arora et al., 2005,
2011; Xiao et al., 2008; Hardison et al., 2010; Leopold Wager
et al., 2015). In addition, macrophages from iNOS deﬁcient
mice or from WT mice cultured with iNOS inhibitors are
unable to control the intracellular proliferation of C. neoformans,
even in the presence of intact ROS production (Leopold Wager
et al., 2015). This reveals that NO, and not ROS, is the
mechanism used by M1 macrophages to control C. neoformans
in mice. However, how well this ﬁnding translates to human
macrophages is a point of contention as the human iNOS
gene is generally epigenetically silenced by CpG methylation,
histone modiﬁcations and chromatin compaction (Gross et al.,
2014). Interestingly, other studies have shown granulomas from
pulmonary tissues in humans and non-human primates contain
iNOS+ macrophages (Facchetti et al., 1999; Mattila et al.,
2013), suggesting that human macrophages are capable of NO
production that could control cryptococcal growth. Further
studies that would characterize the human macrophage response
to Cryptococcus are required to comprehensively address this
question.
Survival and Replication in Macrophages
Following phagocytosis, cryptococci have been shown to
proliferate in the macrophage phagosome (Tucker and
Casadevall, 2002; Voelz et al., 2009), suggesting that these
phagocytes are a preferred niche of the yeast where it can hide
from recognition by the host’s immune system (Johnston and
May, 2013). A clinical study recently examined 65 clinical isolates
of C. neoformans and demonstrated that strains with high rates of
phagocytosis by macrophages with low intracellular proliferation
in vitro coincided with higher CSF fungal burdens and,
paradoxically, long-term survival of HIV patients (Sabiiti et al.,
2014). The strains with high uptake rates were hypocapsular,
had enhanced laccase activity, and were more resistant to
patient antifungal treatment (Sabiiti et al., 2014). This study
demonstrates that cryptococcal-phagocyte interactions are a
major contribution to human clinical presentation and outcome.
In the phagosome, cryptococci are exposed to low pH, ROS
and NO. Studies have shown that C. neoformans does not actively
avoid acidiﬁcation of the phagolysosome in macrophages,
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but actually proliferate better in acidic rather than alkaline
conditions (Diamond and Bennett, 1973; Levitz et al., 1999).
Interestingly, live, but not heat killed, C. neoformans can induce
premature removal of phagosome markers Rab5 and Rab11
(early phagosome markers; Smith et al., 2015). In contrast
to previous studies, Smith et al. (2015) have recently shown
that C. neoformans can hinder signiﬁcant acidiﬁcation of the
phagosome, calcium ﬂux and protease activity, rendering the
phagosome permissive to cryptococcal proliferation in both the
J774.1 macrophage-like cell line and human monocyte derived
macrophages. This study also demonstrated that several virulence
attenuated mutants are able to prevent phagosome maturation
(Smith et al., 2015), suggesting that an unknown mechanism
regulates this process. Studies have shown that incubation of
murine macrophages with C. neoformans can result in host
damage via activation of stress pathway including HIF-1α,
receptor-interacting protein 1, apoptosis-inducing factor and
mitochondrial depolarization (Coelho et al., 2015). A recent study
by Davis et al. (2015) showed that live C. neoformans can cause
lysosomal damage in bone marrow derived macrophages (BMM)
which increases over time (Davis et al., 2015). Stimulation of
BMMs with IFN-γ negated the lysosomal damage and increased
killing of the yeast (Davis et al., 2015), suggesting that the
induction of lysosomal damage is a potential survival strategy
of C. neoformans that is counteracted when macrophages are
activated to the M1 phenotype.
Phospholipase B, a known virulence factor of Cryptococcus,
is a phospholipid modifying enzyme found at the cell surface
(Djordjevic et al., 2005). This enzyme is active under acidic
conditions at 37◦C, as found in macrophage lysosomes. Deletion
of PLB1 in C. neoformans results in attenuated virulence,
increased capsular diameter and size in the phagosome and in the
lung (Evans et al., 2015). PLB1 is also required for proliferation
and survival in macrophages, as well as for dissemination
to the CNS (Evans et al., 2015). Another cryptococcal
protein, Fbp1, is critical for survival and proliferation in the
macrophage phagosome and for dissemination from the lungs
(Liu and Xue, 2014). Fbp1, along with its substrate inositol
phosphosphingolipid-phospholipase C, is required for resistance
to NO and dissemination (Liu and Xue, 2014).
Cryptococcus neoformans is capable of surviving even in a
phagosome with ROS, in part due to absorption of ROS by
the capsule (Zaragoza et al., 2008). In addition, the plasma
membrane high-aﬃnity Cch1-Mid1 calcium channel (CMC) of
C. neoformans promotes cryptococcal survival during exposure
to oxidative stress (Vu et al., 2015). Cch1 mutants have decreased
survival in J774.1A macrophages, however, C. neoformans
deﬁcient in both Cch1 and Mid1 maintain resistance to the
ROS, suggesting a compensatory mechanism in the yeast
(Vu et al., 2015). C. gattii, however, has been shown to
use a novel mechanism in response to ROS. The C. gattii
Vancouver Island outbreak strain R265 induces to tubularization
of its mitochondria, which can facilitate the growth of nearby
“normal” C. gattii cells (Voelz et al., 2014). This enables the
cryptococci to establish an intracellular niche in the macrophage,
increasing pathogenesis. There was no observed correlation
in C. neoformans between mitochondria tubularization and
intracellular proliferation rate (Voelz et al., 2014), suggesting a
unique mechanism of C. gattii.
Trafficking Through the Blood Brain
Barrier
Remarkably, C. neoformans is capable of non-lytic exocytosis,
where the yeast cells burst out of the macrophage without
lysing the phagocyte, again, preventing a response from the host
(Alvarez and Casadevall, 2006; Johnston and May, 2010; Nicola
et al., 2011). The ability of Cryptococcus to proliferate inside
macrophages and then escape is the basis for one hypothesis
as to how C. neoformans traﬃcs across the BBB to cause
meningoencephalitis in immunocompromised hosts. It has been
posited that macrophages act as a “Trojan horse” carrying the
yeast-like cells into the CNS while hidden from the immune
system (Liu et al., 2012). Histological sections of C. neoformans
infected brain tissue show cryptococci within macrophage-like
cells either within or outside capillaries (Chretien et al., 2002).
A second hypothesis is paracellular crossing of the BBB due
to loss of integrity in the tight junctions or injury to the
brain endothelium. These events compromise the BBB, leaving
openings for the yeast cells to cross into the CNS (Ibrahim
et al., 1995; Chen et al., 2003; Olszewski et al., 2004; Charlier
et al., 2005). Third, the transcellular pathway is a hypothesis
in which cryptococcal cells transmigrate via adherence to and
internalization by the brain endothelium from the luminal
surface (blood side) to the abluminal side (brain side) of the BBB
(Chang et al., 2004; Liu et al., 2012; Sabiiti and May, 2012). The
metalloproteaseMpr1 ofC. neoformans is an extracellular protein
that is required for migration across the BBB as it promotes
adherence of the yeast cells to the brain endothelial cells (Vu et al.,
2014).C. neoformans deﬁcient inMpr1 is able to survive in J774.1
macrophages (Vu et al., 2014), providing additional evidence for
the transcellular pathway hypothesis.
Murine studies suggest that C. gattii does not traﬃc to the
brain as readily as C. neoformans (Ngamskulrungroj et al.,
2012), suggesting that dissemination to the CNS is not a
primary target of C. gattii. C. neoformans is phagocytosed more
eﬃciently by THP-1 macrophage-like human cells regardless
of prior stimulation of the macrophage-like cells with IFN-γ
(Sorrell et al., 2015). Remarkably, more C. neoformans-loaded
macrophages traveled across the human brain endothelial cell
line monolayer (a model of the BBB) than C. gattii-loaded
macrophages (Sorrell et al., 2015). C. neoformans also had a
higher rate of expulsion from the THP-1 macrophages (Sorrell
et al., 2015), further validating the Trojan horse hypothesis. All
hypotheses concerning traﬃcking of C. neoformans to the CNS
are supported by strong evidence as discussed above. A likely
explanation is that all mechanisms of traﬃcking are utilized by
C. neoformans to gain access to this privileged site.
DENDRITIC CELLS
Dendritic cells are innate cells that act as sentinels of the
immune system. These cells are phagocytes, but also have the
ability to present antigen to naïve T cells in order to direct
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the adaptive immune response. Initial in vitro studies of DCs
with C. neoformans showed that DCs are involved in detection,
binding, phagocytosis, processing, antigen presentation, T cell
activation, and killing of the organism (Bauman et al., 2000,
2003; Wozniak et al., 2006; Wozniak and Levitz, 2008). Early
studies showed that Langerhans cells and myeloid DCs are
necessary for the induction of protective immune responses
against C. neoformans (Bauman et al., 2000).
Uptake of C. neoformans by DCs requires opsonization with
either anti-capsular antibody or complement, due to the anti-
phagocytic polysaccharide capsule surrounding the cryptococcal
organisms (Kelly et al., 2005). In contrast to encapsulated strains,
phagocytosis of acapsular mutant C. neoformans strains by
DCs requires MR and FcγR II (Syme et al., 2002). Toll-like
receptor 2 (TLR2) and TLR4 are not important in uptake of
C. neoformans or activation of DCs by the fungus (Nakamura
et al., 2006). Following phagocytosis by DCs, cryptococci
translocate to the endosomal compartment followed by the
lysosomal compartment, where they are killed by oxidative
and non-oxidative mechanisms (Kelly et al., 2005; Artavanis-
Tsakonas et al., 2006; Wozniak and Levitz, 2008; Hole et al.,
2012). Studies examining DC lysosomal extract in vitro showed
direct anti-cryptococcal activity (Wozniak and Levitz, 2008; Hole
et al., 2012). Puriﬁed lysosomal enzymes, speciﬁcally cathepsin
B, inhibit cryptococcal growth by cell wall damage followed by
osmotic lysis of the cryptococcal cells (Hole et al., 2012).
During a cryptococcal infection in amouse model, cryptococci
are rapidly internalized by pulmonary DCs (Wozniak et al.,
2006). These DCs increase surface expression of costimulatory
molecules CD80 and CD86 as well as MHC II by D7 post-
infection. DCs isolated from infected lungs present cryptococcal
mannoprotein (MP) to MP-speciﬁc T cells and induced T cell
activation and proliferation ex vivo (Wozniak et al., 2006).
Furthermore, DC phagocytosis of cryptococcal MP in the
presence of the appropriate adjuvant, such as the Th1-type
inducing adjuvant CpG, induces production of protective Th1-
type cytokines (Mansour et al., 2002; Dan et al., 2008a). Upon
uptake of cryptococcal MP, DCs express markers of activation
and maturation including MHC I and MHC II as well as CD40,
CD80, and CD86 (Pietrella et al., 2005; Dan et al., 2008a,b).
MP induces human DCs to secrete IL-12 and TNF-α, which
are associated with the protective Th1-type immune response,
and also leads to Iκβα phosphorylation (Pietrella et al., 2005).
MP-loaded DCs are eﬃcient stimulators of T cells resulting in
CD4 and CD8 proliferation (Pietrella et al., 2005). Additional
studies revealed that the interaction of C. neoformans with
DCs, but not macrophages, induced the production of IL-12
and IL-23, two cytokines associated with protection against
cryptococcosis (Kleinschek et al., 2010). Though macrophages
are capable of presenting antigen to activated T cells, it is the
DCs that are the most eﬃcient antigen presenting cell type to
present C. neoformans mitogen, and only a small number of
DCs are needed for antigen presentation to T cells (Syme et al.,
2002).
Dendritic cells and alveolar macrophages are required
for protection against cryptococcal infection and are needed
early in host defense (Osterholzer et al., 2009a). Depletion
of DCs abrogated the T cell response in mice (Mansour
et al., 2006). Depletion of CD11c+ cells using a CD11cDTR
mouse during cryptococcal infection lead to mortality within
6 days post-infection. Death was associated with neutrophilic
bronchopneumonia and alveolar damage (Osterholzer et al.,
2009a). The recruitment of monocyte-derived DCs into the
lung appears to be dependent on the chemokine receptor
CCR2. CCR2 KO mice infected with C. neoformans show
impaired DC recruitment and the mice developed features
of a Th2-type response including persistent infection,
bronchovascular collagen deposition, and increased IL-
4 production (Osterholzer et al., 2008). CCR2-dependent
recruitment of DCs into C. neoformans infected lungs was due to
increased recruitment of Ly-6Chigh monocytes that diﬀerentiate
into CD11b+ DCs in the lungs (Osterholzer et al., 2009a).
These data suggest that CCR2 is required for the recruitment
of DCs to the lungs and initiation of protective immune
responses during a cryptococcal infection. (Osterholzer et al.,
2008).
Cryptococcal capsule prevents phagocytosis of the organism
(in the absence of opsonization by complement or antibody).
In addition to its role in preventing phagocytosis by DCs and
other phagocytes, the main capsular polysaccharide, GXM, has
profound suppressive eﬀects on immune responses (Yauch et al.,
2006; Zaragoza et al., 2009). Cryptococcal capsule interferes
with both DC activation and maturation (Vecchiarelli et al.,
2003; Lupo et al., 2008; Grijpstra et al., 2009). In contrast,
acapsular strains phagocytosed by DCs induce surface expression
of MHC II and other costimulatory molecules, whereas the
encapsulated strains do not induce activation unless opsonized
by an anti-GXM antibody which is recognized by CD32
and CD16 (Vecchiarelli et al., 2003). Acapsular mutant strain
cap56 induces human DC activation as seen by increased
CD80 and CD86 surface expression (Grijpstra et al., 2009).
In addition to aﬀecting DC maturation, capsular material
can inﬂuence DC gene expression of several cytokines and
chemokines associated with protective responses as well as
genes associated with antigen presentation (Lupo et al., 2008).
Encapsulated strains induce a down-regulation of cytokine genes
and inhibited the induction of the genes for cytokine and
chemokine production as well as antigen presentation (Lupo
et al., 2008).
Although the Th1-type immune response is typically
associated with protective anti-cryptococcal responses, a Th2-
type response may not always be detrimental under certain
conditions. Experimental pulmonary infection of IL-4Rα KO
mice with a C. neoformans serotype D strain resulted in higher
fungal burden compared to WT mice (Grahnert et al., 2014).
Additionally, IL-4Rα KO mice exhibited a defect in DC and
macrophage recruitment due to a reduction in CCL2 and CCL20
chemokines. There was also a reduction in IFN-γ and NO
production in the IL-4Rα KO mice (Grahnert et al., 2014). In
vitro culture of DCs in the presence of C. neoformans and IL-4
resulted in increased IL-12 and reduced IL-10 production by
the DCs (Grahnert et al., 2014). These data in conjunction with
the increased fungal burden in the IL-4Rα KO mice suggest a
beneﬁcial role of IL-4Rα signaling early during infection, whereas
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IL-4Rα signaling during the late phase of infection is detrimental
(Grahnert et al., 2014).
Infection with virulent wild-type C. neoformans strains
naturally induce a strong Th2-type immune response. Urease
produced by C. neoformans directed a strong Th2-type immune
response and lead to a signiﬁcant increase in the amount of
immature DCs that accumulated in the lung-associated lymph
nodes (Osterholzer et al., 2009b). Using a tetramer for chitin
deacetylase 2 (CDA2), Wiesner et al. (2015) were able to isolate
Cryptococcus-speciﬁc Th2 CD4+ T cells and found that chitin
recognition via chitotriosidase leads to the induction of Th2 cells
by DCs. Using multiple DC KO and DC depleted mouse models,
Wiesner et al. (2015) also demonstrated that lung-resident
CD11b+ IRF4-dependent conventional DCs are responsible for
the induction of Th2-type T cells. This indicates that DCs can
have a protective or a non-protective role in the immune response
to C. neoformans. The ability of DCs to react protectively or non-
protectively suggests that these cells are heavily inﬂuenced by
their environment, a fact that could be exploited for development
of novel immunotherapies to combat cryptococcosis.
The interaction of DCs with C. gattii can diﬀer dramatically
from C. neoformans. Human monocyte-derived DCs can kill
C. gattii, but this does not induce DC maturation (Figure 2;
Huston et al., 2013). Even after uptake and processing of C. gattii
by human DCs, they do not increase expression of MHC class
II, CD86, CD83, CD80, and CCR7, which results in defects
in T cell responses (Huston et al., 2013). In addition, DCs
that kill C. gattii do not trigger a release of TNF-α, which
is important for cryptococcal clearance (Huston et al., 2013).
In mice infected with C. gattii, the DCs express much lower
levels of surface MHC II and IL-12 or IL-23 transcripts and
fail to induce eﬀective Th1 and Th17 diﬀerentiation in vitro
compared to mice infected with C. neoformans (Angkasekwinai
et al., 2014). In a DC vaccine model for C. gattii, uptake of an
acapsular mutant by DCs induced expression of costimulatory
molecules and inﬂammatory cytokines (Ueno et al., 2015).
Mice immunized intravenously with BMDCs pulsed with this
acapsular mutant and challenged with C. gattii R265 showed
signiﬁcantly less pathology, reduced fungal burden, signiﬁcantly
increased survival compared to controls. Immunized mice had
signiﬁcantly increased lung and spleen lymphocytes producing
IL-17A, IFN-γ, and TNF-α compared to non-immunized mice,
and protection was signiﬁcantly reduced IFN-γ KO mice (Ueno
et al., 2015). Altogether, prevention of DC maturation by
C. gattii could explain how this yeast causes disease in seemingly
immunocompetent individuals.
NEUTROPHILS
Neutrophils are phagocytes that are recruited to the lungs
during cryptococcal infection and can kill C. neoformans.
However, the importance of neutrophils in protective responses
against cryptococcal infection is unclear. Human neutrophils,
polymorphonuclear leukocytes (PMNs), have been shown to
kill C. neoformans in vitro by both oxidative and non-
oxidative mechanisms (Mambula et al., 2000). Treatment with
inhibitors of the respiratory burst only partially reduced the anti-
cryptococcal activity of human PMNs (Mambula et al., 2000). The
non-oxidative anti-cryptococcal activity of human PMNs was
shown to be mediated by calprotectin and defensins (Mambula
et al., 2000). Mice lacking myeloperoxidase (MPO), an enzyme
associated with neutrophil antimicrobial activity, succumb to the
infection faster thanWTmice upon infection with C. neoformans
either intranasally or intravenously (Aratani et al., 2006). In
vitro, neutrophils migrate toward cryptococcal cells using the
complement C5a-C5aR pathway, and the interaction leads
to phagocytosis and killing of C. neoformans and enhances
activation of Erk and p38 mitogen activated protein kinases
(MAPK) in neutrophils (Sun et al., 2016). Interestingly, inhibition
of p38 MAPK pathway signiﬁcantly decreased neutrophil
migration and cryptococcal killing (Sun et al., 2016). Further
studies showed that neutrophils can migrate into the brain
microvasculature, phagocytose the cryptococcal cells before they
are able to migrate into the brain parenchyma, and re-enter the
circulation, eﬀectively removing the cryptococci from the brain
(Zhang et al., 2015b).
While neutrophils can kill C. neoformans, the pathogen can
also modulate the neutrophil response. Cryptococcal capsular
and cell wall components can inhibit neutrophil migration
(Coenjaerts et al., 2001; Ellerbroek et al., 2004) and can inhibit
the production of neutrophil extracellular traps (NETs; Rocha
et al., 2015). In addition, melanized C. neoformans cells are
able to abrogate the killing activity of neutrophils by interfering
with sphingomyelin synthase (SMS) activity, which is required
for cryptococcal killing by neutrophils (Qureshi et al., 2010,
2011). Cryptococcal cells can prevent neutrophil migration by
secreting capsular components, which activates microglia to
produce IL-8 (a neutrophil chemoattractant) and also reduces the
expression of L-selectin (CD62L) on the neutrophil surface in
humans with disseminated cryptococcosis, reducing neutrophil
migration. Neutrophil endothelial rolling and production of
surface expression of TNF-α receptor are also impaired due to
cryptococcal capsular polysaccharide (reviewed in Urban et al.,
2006).
Neutrophil depletion in mice during protective immune
responses does not aﬀect pulmonary fungal burden, indicating
that neutrophils are not required for cryptococcal clearance
(Wozniak et al., 2012). These data further support the
observation by Mednick et al. (2003) that neutropenic mice
given a pulmonary C. neoformans infection survived signiﬁcantly
longer than control mice with intact neutrophils, therefore
indicating that neutrophils are not necessary for protective
responses against cryptococcal infection. Furthermore, the
presence of neutrophils in the lungs during cryptococcal infection
can cause additional damage to the host (Osterholzer et al.,
2009a).
In a rat model of C. gattii infection, there is an early
recruitment of neutrophils into the lungs, but phagocytosis
of cryptococci is not observed (Wright et al., 2002). C. gattii
inhibits or fails to induce migration of neutrophils to the site of
infection, thereby impeding an inﬂammatory response (Cheng
et al., 2009). In addition, encapsulated C. gattii environmental
strains that produced extracellular ﬁbrils (which may be
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FIGURE 2 | Dendritic cell cryptococcal killing and antigen presentation. Immature dendritic cells efficiently phagocytose and kill opsonized Cryptococcus
neoformans cells, leading to DC maturation, shown by upregulation of costimulatory molecules (MHC II, CD80, CD86) and antigen presentation to CD4+ T cells. In
contrast, C. gattii can also be phagocytosed and killed by DCs, but leads to a downregulation of DC maturation and expression of costimulatory molecules MHC II,
CD80, CD86 and reduces antigen presentation to T cells.
important in cryptococcal cell communication or cryptococcal-
host communication) were resistant to neutrophil killing, even
when neutrophils produced NETs (Springer et al., 2010).
PATTERN RECOGNITION RECEPTORS
In order for the phagocytic cell to take up a pathogen, it has
to recognize that the pathogen is foreign. The cell does this by
recognition of PAMPs via germline-encoded PRRs present either
on the cell surface or within distinct intracellular compartments.
These PRRs include TLRs, C-type lectin receptors (CLRs),
NOD-like receptors and others. PRRs recognize a wide range
of bacterial, fungal, and viral PAMPS, including lipopeptides,
peptidoglycan, β-glucans mannan, and pathogen DNA and RNA
(Figure 3).
One of the main virulence factors of Cryptococcus is the anti-
phagocytic polysaccharide capsule (Zaragoza et al., 2009). TLR2
and TLR4 have been shown to recognize cryptococcal GXM
(Shoham et al., 2001; Yauch et al., 2004, 2005). GXM was shown
to bind to both TLR2 and TLR4 with the co-receptor CD14
but failed to activate the MAPK pathway and produce TNF-α
(Shoham et al., 2001). TLR2 KO mice were more susceptible
to cryptococcal infection than WT control mice; however, there
was no diﬀerence in survival in C3H/HeJ mice which have a
non-functional TLR4, compared to control mice (Yauch et al.,
2004). Mice deﬁcient in the adaptor molecule MyD88 (myeloid
diﬀerentiation primary response gene 88), which is used by all
TLRs except TLR3, exhibited a signiﬁcant increase in mortality
compared toWTmice and succumbed to a cryptococcal infection
faster than the TLR2 KOmice, suggesting that MyD88 is required
for protection against C. neoformans (Yauch et al., 2004; Biondo
et al., 2005). Peritoneal macrophages from TLR2 KO or MyD88
KO mice exhibit reduced production of TNF-α when cultured
with C. neoformans in vitro (Biondo et al., 2005). Furthermore,
TLR2 KO and MyD88 KO mice showed decreased expression
of TNF-α, IFN-γ, and IL-12p40 transcripts in the lungs, brain,
and spleen during infection with C. neoformans (Biondo et al.,
2005). Peripheral blood mononuclear cells (PBMCs) isolated
from patients with cryptococcal meningitis exhibited a signiﬁcant
reduction in TLR2 expression compared to healthy control
PBMCs and blocking TLR2 on PBMCs led to a reduction in
IL-12p70 and IFN-γ when stimulated with Cryptococcus (Zhang
et al., 2015a). While TLR2 and TLR4 can recognize cryptococcal
GXM, these receptors may only play a minor role in protection
to C. neoformans infection (Nakamura et al., 2006). What is clear
is that MyD88 is necessary for protection against C. neoformans,
suggesting that other TLRs are required.
TLR9 is an endosomal PRR that recognizes unmethylated
pathogen CpG DNA following its ingestion and degradation
by the immune cell. Uptake of C. neoformans leads to the
recruitment of TLR9 to the fungal phagosome (Kasperkovitz
et al., 2011), and TLR9 KO mice were more susceptible to
cryptococcal infection thanWT control mice (Wang et al., 2011).
Mice treated with the TLR9 antagonist CpG-ODN 3 days before
infection with C. neoformans strain 52D, a moderately virulent
clinical isolate, had reduced fungal burden and pulmonary
eosinophilia as well as increased IFN-γ production by CD8+
T cells (Edwards et al., 2005). Cryptococcal DNA can activate
DCs via TLR9 recognition to produce IL-12p40 and express
CD40 (Nakamura et al., 2008). This activity was dependent
on the methylation of the DNA as methylase treatment of the
DNA led to a reduction of IL-12p40 produced by the DCs.
Genetic ablation of TLR9 or MyD88 completely abrogated the
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FIGURE 3 | Cryptococcal Pattern Recognition Receptors. Cryptococcus has multiple pathogen associated molecular patterns (PAMPs) that are recognized by
many types of pattern recognition receptors (PRRs). GXM is recognized by TLR2 and TLR4. Cryptococcal mannan can be recognized by the C-type lectin receptors
Dectin-2, DC-SIGN, and CD206 or mannose receptor. B-glucans found in the cryptococcal cell wall can be recognized by Dectin-1, and cryptococcal DNA can be
recognized by the endosomal receptor TLR9.
eﬀect of cryptococcal DNA on the DCs, demonstrating that
DNA recognition and activation by DCs was dependent on
TLR9 and MyD88 (Nakamura et al., 2008). Culture supernatants
from C. neoformans are able to dampen the DC response to
cryptococcal DNA (Yamamoto et al., 2011). The inhibitory eﬀects
of the supernatants were reduced by heat or trypsin treatment
indicating that C. neoformans secretes proteinaceous molecules
that suppress activation of DCs by cryptococcal DNA (Yamamoto
et al., 2011). It was shown that the nucleic acid sequence for
cryptococcal URA5 speciﬁcally activates DCs through a TLR9-
mediated signaling pathway using a mechanism that is diﬀerent
than the canonical CpG motif that is associated with TLR9
signaling (Tanaka et al., 2012). Cryptococcal infection in TLR9
KO mice leads to decreased IFN-γ and TNF-α and an increase in
IL-4 compared with WTmice (Zhang et al., 2010). The increased
IL-4 in C. neoformans-infected TLR9 KO mice led to increased
M2 macrophage activation markers arginase and FIZZ1 and a
decrease in M1 macrophage marker iNOS compared to WT
mice (Zhang et al., 2010). Ablation of TLR9 led to reduction of
CD11b+ DCs and CCL7 in the lungs during the aﬀerent phase
(week 1) and reduced the pulmonary accumulation of CD11b+
DCs during the eﬀerent phase [week 3; (Qiu et al., 2012)].
The fungal cell surface is covered in carbohydrates including
β-glucans and mannan which are recognized by C-type lectin
receptors (CLRs). The β-glucan CLR Dectin-1 has been shown
to be important in protection to Aspergillus, Candida, and
Pneumocystis infections (Steele et al., 2005; Saijo et al., 2007;
Taylor et al., 2007). Dectin-1 has been shown to bind to
the β-glucans found on cryptococcal spores (Giles et al.,
2009), however, there was no signiﬁcant diﬀerence in disease
progression in Dectin-1 KO mice compared to WT mice during
cryptococcal infection indicating that Dectin-1 may not be
required for host defense to C. neoformans (Nakamura et al.,
2007).
There are multiple receptors that recognize mannan including
the CLRs Dectin-2, MR (CD206), and DC-SIGN. Dectin-2
has been shown to recognize mannan from multiple fungal
organisms (Hardison and Brown, 2012). Dectin-2 KO BMDCs
incubated with C. neoformans failed to produce IL-12p40 and
TNF-α as well as failed to increase surface expression of CD86
and MHC II compared to WT BMDCs (Nakamura et al., 2015).
In addition, Dectin-2 KO mice infected with C. neoformans
exhibited higher levels of Th2-type cytokines which are associated
with non-protective immune responses compared to infected
WT mice (Nakamura et al., 2015). Both MR and DC-SIGN
have been shown to recognize heavily mannosylated cryptococcal
mannoproteins (Mansour et al., 2006). Human and murine DCs
are able to recognize and capture cryptococcal MPs by a mannose
receptor (CD206) mediated process (Mansour et al., 2006).
MR KO mice succumb to C. neoformans infection signiﬁcantly
faster compared to WT mice (Dan et al., 2008a). Cryptococcal
MPs in combination with TLR ligands enhanced production of
proinﬂammatory cytokines and chemokines from DCs as well as
enhanced MP-speciﬁc MHC II-restricted CD4+ T-cell responses
(Dan et al., 2008a). Increased surface expression of CD206,
which is upregulated on M2 macrophages, results in increased
phagocytosis but is accompanied by decreased intracellular
killing and TNF-α production (Dan et al., 2008a).
TARGETING MACROPHAGES AND DCS
FOR VACCINES/IMMUNOTHERAPIES
As demonstrated in the above discussion, innate phagocytes
play a pivotal role in the recognition of Cryptococcus, anti-
fungal activity, and prevention of cryptococcosis. Identiﬁcation
of the speciﬁc PRRs utilized by innate immune cells to
recognize Cryptococcus and lead to the yeast’s internalization and
destruction could provide a novel target for treatment. Studies
designed to elucidate the host PRR must keep in mind that
diﬀerent immune cells could utilize diﬀerent PRRs to recognize
Cryptococcus. In addition, the PAMPs for C. neoformans and
C. gattii may not be the same. More study is required to identify
the speciﬁc PAMP and PRR combination that elicits protective
immune responses.
As C. gattii tends to cause disease in immunocompetent
individuals, traditional methods of vaccination that elicit a
memory T cell response could prove fruitful, however, this
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has not yet been achieved. High-risk groups for cryptococcosis
caused by C. neoformans, including AIDS patients, are deﬁcient
in CD4+ T cells. Nonetheless, recent evidence does suggest
that development of a vaccine against Cryptococcus is feasible
(reviewed in Leopold Wager and Wormley, 2015). It has been
shown that CD8+ T cells can compensate for the loss of
CD4+ T cells (Lindell et al., 2005), thus targeting this adaptive
immune cell population is possible. Interestingly, immunization
of mice with the IFN-γ producing C. neoformans strain H99γ
leads to protection in B cell deﬁcient mice (Wozniak et al.,
2009) as well as WT BALB/c mice that are depleted of both
CD4+/CD8+ T cells during the challenge phase (Wozniak
et al., 2011b), suggesting that protection can be achieved in
the absence of traditional adaptive immunity. A relatively new
concept allows for the generation of “innate memory” or “trained
immunity.” This memory occurs in innate cells, including
NK cells and monocytes/macrophages in response to Candida
albicans or simply by “training” via exposure to β-glucans
(Quintin et al., 2012). The “trained” monocytes/macrophages
have enhanced cytokine recall responses when challenged with
C. albicans. The protective responses in these cells are non-
speciﬁc and confer heightened responses following secondary
exposure to an antigen, including C. albicans. Altogether, this
evidence is proof-of-concept that protection can be achieved in
immunocompromised individuals.
A novel delivery platform utilizing glucan particles is a
promising approach to vaccine design that targets innate
phagocytes, including macrophages and DCs. The glucan
particles are isolated from baker’s yeast (Saccharomyces) and
are puriﬁed, hollow, and porous cell wall shells composed
mostly of β-1,3-glucan (reviewed in Levitz et al., 2015).
These stimulate dectin-1 and other PRRs on phagocytes
and induce the production of protective cytokines such as
IFN-γ and IL-17A (Huang et al., 2009, 2010, 2012, 2013;
reviewed in Levitz et al., 2015). The glucan particles can be
loaded with proteins, siRNA, DNA, and other small molecules.
Immunization with these particles loaded with synthetic peptides
of Coccidioides results in elevated Th1 and Th17 responses
following challenge with Coccidioides posadasii (Hurtgen et al.,
2012). A recently published study loaded the glucan particles
with soluble alkaline extracts from two diﬀerent attenuated
Cryptococcus strains, acapsular strain cap59 and strain cda123
which lacks cell wall chitosan. Immunization of mice with
the cryptococcal-loaded glucan particles resulted in increased
survival following challenge with C. neoformans Kn99 and
was associated with Th1 and Th17 immune responses (Specht
et al., 2015). In addition, mice immunized with glucan particles
loaded with cap59 extracts were partially protected against
challenge with C. gattii strain R265 (Specht et al., 2015).
Thus, these studies have identiﬁed novel vaccine candidates
in the alkaline extracts from C. neoformans, and suggest that
administration via this delivery system is promising for novel
vaccine development.
Immunodominant cryptococcal proteins have recently
been identiﬁed from both C. neoformans and C. gattii
(Chaturvedi et al., 2013, 2014). Intranasal immunization of
mice with cryptococcal cell wall and/or cytoplasmic protein
fractions from C. gattii or immunodominant protein fractions
from C. neoformans extended survival following challenge
of the respective Cryptococcus sp (Chaturvedi et al., 2013,
2014). In addition, certain mannoproteins have been shown
to elicit vaccine-mediate immunity, extending survival of
C. neoformans infected mice (reviewed in Chaturvedi and
Wormley, 2013; Levitz et al., 2015). PBMCs from patients
who have recovered from cryptococcosis are able to proliferate
and produce pro-inﬂammatory cytokines when stimulated
with mannoproteins (Levitz and North, 1997). These proteins
and other highly conserved antigens, including heat shock
proteins, β-glucan, and glycolytic enzymes, are potential
targets for the development of subunit vaccines. Vaccines
that utilize recombinant proteins must take into account the
posttranslational modiﬁcations of these cryptococcal proteins
and how that aﬀects immunogenicity.
Speciﬁc targeting of macrophage phenotype also has the
potential for development of vaccines that would target the
host and not the organism, thus limiting selective pressure
on the fungus. Treatment of macrophages with IFN-γ results
in the M1, fungicidal phenotype, while stimulation with IL-
4/IL-13 results in the M2, cryptococcal growth-permissive
phenotype (Olszewski et al., 2010; Leopold Wager and Wormley,
2014). It was recently demonstrated that macrophages ﬁrst
polarized to an M2 phenotype with IL-4 can be repolarized
to an M1 phenotype following IFN-γ treatment (Davis et al.,
2013), demonstrating the plasticity of macrophages in response
to their cytokine milieu. These repolarized macrophages are
fully functional M1 macrophages, produce NO and are anti-
cryptococcal (Davis et al., 2013). Additionally, immunization
of mice with the C. neoformans IFN-γ-producing strain
(H99γ) and challenge with WT C. neoformans H99 results in
complete protection and M1 macrophage activation (Hardison
et al., 2012). This macrophage polarization is occurring even
without exogenous IFN-γ produced by the organism, providing
evidence for memory T cell responses and possibly for
“innate memory” in the macrophages. Recent studies have
also shown that DCs are capable of polarizing to a pro-
inﬂammatory DC1 phenotype and anti-inﬂammatory DC2
phenotype, which may also play a role in cryptococcal immune
responses (Guiducci et al., 2005; Cook et al., 2012). Taken
together, these studies suggest that targeting the polarization
of macrophages and/or DCs toward an anti-cryptococcal
phenotype could provide a novel mechanism for the induction
of protective responses against Cryptococcus. Thus, these
innate phagocytes that are critical for the development of
protective responses against cryptococci could also be the key
to development of novel vaccines and/or immunotherapies to
prevent cryptococcosis.
CONCLUSION
The interactions between the host and the pathogen are critical
for early control of the infection and, thus, the ability of
the host to clear the infection. Cryptococcus has developed
numerous eﬀective strategies to either evade the immune system
Frontiers in Microbiology | www.frontiersin.org 10 February 2016 | Volume 7 | Article 105
Leopold Wager et al. Phagocytes and Cryptococcal Disease
or to modulate the host cells allowing survival and replication
within the phagocyte. There is still much to learn about
how the host cells react to Cryptococcus and how they allow
themselves to be manipulated by the fungus, as well as how
the yeast expertly modulates and evades the immune system.
In addition, there is an added complexity when the site of
infection and the stage of disease is taken into account. Future
research should aim to determine the roles of speciﬁc molecular
interactions between Cryptococcus and phagocytes, and how
these interactions either contribute to or prevent pathogenesis.
A comprehensive understanding of these small, yet substantial
interactions will undoubtedly result in eﬀective anti-cryptococcal
therapies that will likely be translatable to other intracellular
infections which rely so desperately on the early responses of
phagocytes.
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